Angiodynamics, Inc. · NASDAQ:ANGO
Angiodynamics — Q3 FY2021 Earnings Presentation
8 slides from Angiodynamics's earnings presentation, Mar 30, 2021
Slide 1: Third Quarter 2021 Earnings Presentation
ANGIODYNAMICS Third Quarter 2021 Earnings PresentationMarch 30, 2021 1
Slide 2: Forward-Looking Statement
2 Forward-Looking Statement Notice Regarding Forward-Looking StatementsThis presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial position, results of operations,
Slide 3: Corporate Developments – Q3 Highlights
Corporate Developments – Q3 Highlights 3 27% Growth in AngioVac $3.3 million in Auryon sales NanoKnife disposable growth: US 12% YOY; worldwide decline of 7% YOY Procedural volumes negatively impacted in January and first half of February Began to rebound in the second half of FebruaryAngioVac and A
Slide 4: Third Quarter FY2021 Highlights
Third Quarter FY2021 Highlights $ in thousands (except per share data) Q3 FY2021 Q3 FY2020 YOY Change Revenue $71,182 $69,780 2.0% Gross Margin 54.1% 57.8% (370 bps) Net Loss ($3,544) ($5,709) $2,165 GAAP EPS ($0.09) ($0.15) $0.06 Adjusted EPS $0.02 $0.01 $0.01 Adjusted EBITDA $5,379 $3,790 $1,589 C
Slide 5: Third Quarter FY2021 Results (unaudited)
Third Quarter FY2021 Results (unaudited) $ in thousands (except per share data) Q3 FY2021 Q3 FY2020 Change YTD FY2021 YTD FY2020 Change Revenue Vascular Interventions and Therapies Vascular Access Oncology United States International $71,182$33,251$24,813$13,118$58,654$12,528 $69,780$30,552$24,642$1
Slide 6: GAAP to Non-GAAP Reconciliation
GAAP to Non-GAAP Reconciliation 6
Slide 7: Reconciliation of GAAP to Non-GAAP Net Income and EPS
Reconciliation of GAAP to Non-GAAP Net Income and EPS Reconciliation of Net Loss to Adjusted EBITDA Includes costs related to merger and acquisition activities, restructurings, and unusual items, including asset impairments and write-offs, certain litigation, and other items.Deferred financing fees
Slide 8: AngioDynamics
®D angiodynamics